

Only for the use of Medical Professionals

Fluver®

Flunarizine

Composition

Fluver® 5 mg tablet: Each tablet contains Flunarizine 5 mg as Hydrochloride BP.

Fluver® 10 mg tablet: Each tablet contains Flunarizine 10 mg as Hydrochloride BP.

Pharmacology

Fluver® is the preparation of Flunarizine which is a difluorinated derivative of cinnarizine. It is a selective calcium channel antagonist. By reducing excessive transmembrane influx of calcium **Fluver®** prevents cellular calcium overload. It does not interfere with normal cellular calcium homeostasis. **Fluver®** also has some antihistaminic and sedative properties. It binds at an affinity of 99% to plasma protein. is the preparation of Atenolol. It is a synthetic, β -selective (cardioselective) adrenoceptor blocking agent without membrane stabilizing or intrinsic sympathomimetic activity.

Indication

Fluver® is indicated for the following conditions –

- Prophylaxis of classic (with aura) or common (without aura) migraine.
- Symptomatic treatment of vestibular vertigo owing to a diagnosed functional disorder of the vestibular system.
- Symptomatic treatment of dizziness, tinnitus, vertigo and headache owing to cerebral ischemia.
- Symptomatic treatment of intermittent claudication, Raynaud's phenomenon, paresthesiae, cold extremities, nocturnal cramp and trophic disorders owing to ischemia of the limbs.
- As add-on therapy to existing anticonvulsant medication in the refractory seizures.

Dose and administration

Route of administration: **Fluver®** should be taken in oral route.

Migraine: The recommended dose of **Fluver®** for migraine prophylaxis is 10 mg orally once daily in adults and 5-10mg once daily in children. If a patient responds satisfactorily to the starting dose and if a maintenance treatment is required, the dose of **Fluver®** should be decreased so that each week the patient has 5 days of treatment at the same daily dose of **Fluver®** and 2 successive drug free days. Even if the prophylactic treatment is successful and well tolerated it should be interrupted after 6 months and reinitiated only if migraine relapses.

Vertigo and peripheral vascular disease: For vertigo, peripheral vascular disease and refractory epilepsy, treatment with **Fluver®** is started with 10mg dose at bedtime for patients younger than 65 years of age and with 5mg dose at bedtime for patients older than 65 years. For vertigo dosage should be increased up to 20mg three times daily and for refractory epilepsy it should be increased up to 100mg daily with the maintenance dose targeted to produce serum levels of 60 g/litre.

Patients with hepatic disease: Since flunarizine is primarily metabolized in the liver, dosage adjustment is required in hepatic insufficiency.

Contraindication

Flunarizine is contraindicated in patients with hypersensitivity to flunarizine or cinnarizine, depressive illness, Parkinson's disease or extra pyramidal disorders.

Warning and precaution

Discontinue therapy if fatigue increases progressively.

Side effects

Drowsiness or fatigue, weight gain, increased appetite, depression and extra pyramidal symptoms may occur.

Use in pregnancy and lactation

Pregnancy: The safety of flunarizine for use in pregnancy has not been established.

Lactation: No data is available on the excretion of flunarizine in human breast milk. Breast feeding should therefore be avoided in women taking flunarizine.

Drug interaction

Drug interaction with medication: Alcohol, hypnotics or tranquilizers may interact with flunarizine.

Drug interaction with food and others: Not applicable.

Storage

Store in a cool and dry place protected from light. Keep away from the reach of children.

Packing

Fluver® 5 mg tablet: Carton of 100 tablets in blister.

Fluver® 10 mg tablet: Carton of 100 tablets in blister.

® Registered Trade Mark



Advanced Chemical

Industries Limited

7, Hajeegonj Road, Godnol
Narayanganj, Bangladesh